AUS
NZ
UK
CA
USA
IND
Ramsay Health Care Limited (ASX:RHC), a leading private hospital operator in Australia, has announced the expiration of 31,159 performance rights under the RHCAB code across three separate cessation dates in May and June 2026. These rights lapsed because the required vesting conditions were either unmet or became impossible to fulfill. The company confirmed that no payment was made in relation to these cessations. Following this update, Ramsay’s outstanding unquoted performance rights total 772,944, while the number of ordinary fully paid shares stands at 230,829,811.
Key Points
- Company: Ramsay Health Care Limited (ASX:RHC)
- 31,159 RHCAB performance rights lapsed over three cessation dates: 29 May 2026, 25 June 2026, and 30 June 2026
- Lapse occurred due to unmet or impossible-to-meet vesting conditions
- No consideration was paid by Ramsay in connection with these cessations
- Remaining RHCAB performance rights on issue: 772,944
- Ordinary fully paid shares after these changes: 230,829,811
- Investors should monitor for further lapse notifications or updates on Ramsay’s executive remuneration plans
Performance Rights Expire in Three Separate Tranches Between May and June 2026
In a company update lodged on 6 July 2026, Ramsay Health Care detailed that the 31,159 RHCAB performance rights expired in three distinct batches over a five-week span. The first batch of 4,296 rights lapsed on 29 May 2026. The largest lapse occurred on 25 June 2026, involving two separate line items of 16,133 and 4,448 rights respectively. The final lapse of 6,282 rights took place on 30 June 2026.
The staggered timing indicates these rights were likely granted under different award tranches or performance periods rather than being a single mass cancellation. The announcement did not disclose the identity of the holders or the precise performance targets for each tranche, only confirming that in all cases, vesting conditions were unmet or impossible to satisfy.
Reasons Behind the Lapse of Ramsay’s RHCAB Performance Rights Without Share Conversion
Performance rights are commonly used as long-term incentives in executive remuneration at major ASX-listed companies. They grant participants a conditional right to receive ordinary shares if specified performance or service conditions are met within a defined period. Failure to meet these conditions by the test date results in the rights lapsing with no shares or cash awarded.
Ramsay confirmed that no consideration was paid in relation to the three cessation events, meaning holders of the lapsed rights received no monetary compensation. The announcement did not specify the exact performance metrics, such as earnings per share growth or total shareholder return targets, attached to these RHCAB tranches.
31,159 RHCAB Rights Removed From Ramsay’s Unquoted Equity Capital
The three cessation events combined reduce Ramsay’s unquoted equity securities by 31,159 performance rights. The summary figure matches the total of individual line items: 4,296 rights lapsed on 29 May 2026, and 16,133 plus 4,448 plus 6,282 rights lapsed between 25 and 30 June 2026.
Notably, the summary groups the June lapses differently from the detailed section, showing 20,581 rights lapsing on 25 June and 6,282 on 30 June. Both presentations total 31,159. Investors tracking Ramsay’s dilutive equity instruments should note these rights are permanently extinguished and will not convert into shares.
Ramsay’s Remaining Performance Rights and Current Ordinary Share Capital
After the lapse of 31,159 rights, Ramsay has 772,944 RHCAB performance rights outstanding as unquoted equity securities. These represent conditional entitlements that may convert into ordinary shares if vesting conditions are met in the future.
Ramsay’s ordinary fully paid shares (ASX:RHC) currently total 230,829,811. Additionally, the company has 2,600,000 RHCPA perpetual subordinated converting preference securities outstanding, described as "TRANS PREF 6-BBSW+ 4.85% PERP SUB RED T-10-10." The filing notes that figures in Part 3 are system-generated and may not reflect real-time issued capital if other filings are being processed simultaneously.
No Immediate Dilution Impact for Shareholders From Lapsed Rights
For shareholders, the lapse of performance rights generally has a neutral to positive short-term effect by removing potential future dilution. Had these 31,159 rights vested and converted, the total share count would have increased slightly, diluting existing ownership. With these rights now expired, that dilution risk is eliminated.
The lapsed rights represent a very small fraction of Ramsay’s 230,829,811 ordinary shares, so the direct impact on capital structure is minimal. However, the lapse may reflect challenges in achieving performance benchmarks tied to executive incentives, though the announcement does not comment on this.
Implications of Unmet Vesting Conditions on Ramsay’s Performance Outcomes
The stated reason for all three tranches’ lapse is consistent: "lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied." This standard regulatory language confirms the performance hurdles for these awards were not met within the required timeframe.
Ramsay Health Care has faced operational challenges recently, including cost pressures, workforce issues, and changes in private health insurance across its Australian and international hospital networks. Whether these factors contributed to unmet vesting conditions is not addressed in the announcement and would require review of the company’s financial disclosures and remuneration reports.
Overview of Appendix 3H Filing Requirements for ASX Entities Like Ramsay
The Appendix 3H is an ASX-mandated form requiring listed companies to notify the exchange when previously issued securities cease to exist due to lapse, cancellation, conversion, or other reasons. For performance rights, companies must file Appendix 3H when rights lapse because conditions are unmet, ensuring market transparency regarding issued capital and potential equity obligations.
Ramsay lodged this Appendix 3H on 6 July 2026, covering lapses occurring between 29 May and 30 June 2026. Consolidating multiple cessation events in one filing is common, often coinciding with financial year-end reporting periods. The June 2026 lapses align with Ramsay’s financial year-end, explaining the grouped disclosure.
Ramsay Health Care’s Capital Structure Post-July 2026 Update
Following these cessation events, Ramsay’s capital structure includes three security classes. The primary quoted class is 230,829,811 ordinary fully paid shares (RHC), which determine the company’s market capitalization. The second quoted class consists of 2,600,000 RHCPA perpetual subordinated preference securities with a floating rate of bank bill swap rate plus 4.85% per annum.
The unquoted class comprises 772,944 RHCAB performance rights, which are not traded on ASX and do not affect market capitalization directly but represent contingent equity obligations that could increase share count if vested. Analysts modeling fully diluted shares would include these rights alongside other unquoted instruments.
Investor Outlook and Upcoming Disclosure Milestones for Ramsay Health Care
The immediate effect of this update on Ramsay’s share price is unclear. Notifications of performance rights lapsing are routine and typically not material price-sensitive events. However, they provide insight for investors monitoring executive remuneration, management incentives, and potential equity dilution.
Investors may focus on Ramsay’s forthcoming full-year financial results, which will cover the period ending 30 June 2026, coinciding with two of the three lapse events. The accompanying remuneration report is expected to detail long-term incentive plans, specific performance conditions, and vesting outcomes. Additional Appendix 3H filings may follow if further performance rights lapse in coming months.
